LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two patients in the ...

Anova to manage delivery of Phase 1 study of Kromastat (formerly known as NBS-M001) for the treatment of relapsed or refractory cutaneous and peripheral T-cell lymphoma Anova to accelerate ...

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, has ...

Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...

Denovo Biopharma LLC identified a novel genetic biomarker Denovo Genomic Marker 7 (DGM7 TM) based on data from a prior clinical trial in patients with recurrent disease believed to predict responders ...

has been chosen to participate in a landmark national prostate cancer study. The goal of the two-year study is to determine the best treatments for prostate cancer. The study will look specifically at ...